IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
Open Access
- 9 April 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
Abstract
Recent studies in distinct preclinical tumor models have established the nucleotide synthesis enzyme inosine-5′-monophosphate dehydrogenase (IMPDH) as a viable target for antitumor therapy. IMPDH inhibitors have been used clinically for decades as safe and effective immunosuppressants. However, the potential to repurpose these pharmacological agents for antitumor therapy requires further investigation, including direct comparisons of available compounds. Therefore, we tested structurally distinct IMPDH inhibitors in multiple cell and mouse tumor models of the genetic tumor syndrome tuberous sclerosis complex (TSC). TSC-associated tumors are driven by uncontrolled activation of the growth-promoting protein kinase complex mechanistic target of rapamycin (mTOR) complex 1 (mTORC1), which is also aberrantly activated in the majority of sporadic cancers. Despite eliciting similar immunosuppressive effects, the IMPDH inhibitor mizoribine, used clinically throughout Asia, demonstrated far superior antitumor activity compared with the FDA-approved IMPDH inhibitor mycophenolate mofetil (or CellCept, a prodrug of mycophenolic acid). When compared directly to the mTOR inhibitor rapamycin, mizoribine treatment provided a more durable antitumor response associated with tumor cell death. These results provide preclinical support for repurposing mizoribine, over other IMPDH inhibitors, as an alternative to mTOR inhibitors for the treatment of TSC-associated tumors and possibly other tumors featuring uncontrolled mTORC1 activity.Funding Information
- National Institutes of Health (P01CA120964)
- National Institutes of Health (R35CA197459)
- National Institutes of Health (P30CA006516)
- Tuberous Sclerosis Alliance (19464)
This publication has 63 references indexed in Scilit:
- A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissueNature Protocols, 2012
- A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphatesNucleic Acids Research, 2011
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1Molecular Cell, 2010
- Quantitation of cellular deoxynucleoside triphosphatesNucleic Acids Research, 2009
- Estrogen promotes the survival and pulmonary metastasis of tuberin-null cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Antiproliferative effects of AVN944, a novel inosine 5-monophosphate dehydrogenase inhibitor, in prostate cancer cellsInternational Journal of Cancer, 2008
- Global Regulation of Nucleotide Biosynthetic Genes by c-MycPLOS ONE, 2008
- The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2Molecular and Cellular Biology, 2008
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or LymphangioleiomyomatosisThe New England Journal of Medicine, 2008
- Safety, tolerability and pharmacokinetics of higher‐dose mizoribine in healthy male volunteersBritish Journal of Clinical Pharmacology, 2006